WORCESTER, Mass., June 29, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that the company has reviewed the positive data from its bioequivalent study with MetControl(tm), its proprietary metformin chewing gum product study conducted in November 2008. Results of the fully compliant ICH-GCP conducted study indicate that MetControl(tm) chewing gum and traditional Metformin tablets are bioequivalent in respect of both the rate and the extent of systemic absorption. Management believes the results provide convincing evidence that MetControl(tm) and Metformin tablets are therapeutically equivalent and therefore interchangeable.
